Tsuchimoto Kim R, DIR, reported an open-market or private sale at Monopar Therapeutics involving 700.000000 shares for an estimated $77455.00. Reported holdings after the transaction were 9686.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
No officer title
This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to pro…
0 other filings
0 recent txs